Product Data Sheet

Ragaglitazar

Catalog No. A39992

main product photo
Ragaglitazar is a dual agonist of PPARα and PPARγ, exhibiting strong lipid-lowering and insulin-sensitizing properties. This compound has been shown to enhance glycemic control and improve lipid profiles in animal models of type 2 diabetes, making it a valuable tool for research in metabolic disorders and potential therapeutic applications in diabetes management.
Chemical Information
Catalog NumA39992
M. Wt419.47
FormulaC25H25NO5
Purity>98%
Storageat -20 °C 3 years (powder form); at -20 °C 6 months (Solution base)
CAS No.222834-30-2
Synonyms(-)-DRF 2725; NNC 61-0029
SMILESO=C(O)[C@@H](OCC)CC1=CC=C(OCCN2C3=C(C=CC=C3)OC4=CC=CC=C24)C=C1
Biological Activity
DescriptionRagaglitazar is a dual agonist of PPARα and PPARγ, exhibiting strong lipid-lowering and insulin-sensitizing properties. This compound has been shown to enhance glycemic control and improve lipid profiles in animal models of type 2 diabetes, making it a valuable tool for research in metabolic disorders and potential therapeutic applications in diabetes management.
RETURN POLICY
Adooq’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Adooq products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Adooq Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Adooq products are stable under the recommended conditions.